Salivation after stroke

Zalialova Z.A.

doi:https://doi.org/10.17116/jnevro20171171185-89

Close metadata

Recommended articles:

Impact of botulinum therapy on long-term control of cervical dystonia symptoms and patient satisfaction with treatment: results of the international prospective observational study INTEREST IN CD2 in Russian subgroup of patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):74-82

Primary progressive aphasia in the neurologist practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):61-66

Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80

Prevalence and characteristics of risk factors for cerebrovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124

Approaches to medical rehabilitation of patients with post-stroke hemianopsia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):20-25

Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cerebrovascular accidents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):26-31

Effectiveness of “brain—computer” interfaces with biofeedback in the rehabilitation of cognitive impairment after a stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):54-60

Frailty in patients with atrial fibrillation: diagnosis, management, prevention and influence on prognosis. Russian Cardiology Bulletin. 2025;(1):5-12

Contemporary aspects of brain protection in aortic arch surgery. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):164-173

Prediction of restoration of functional activity of paretic limbs in patients who have suffered an ischemic stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(3):31-40

Abstract:

Salivation after stroke (sialorrhea, hypersalivation, ptyalism) can be caused by the overproduction or a lack of utilization of saliva. Patients after stroke often have sialorrhea as a result of dysphagia. Neurogenic dysphagia in acute period after stroke occurs in 25—65% of patients. The mortality rate among people with post-stroke dysphagia and tube feeding ranges from 20 to 24%. Patients who suffering from profuse salivation have difficulties with articulation and swallowing, bad breath, irritation and maceration of perioral area, contamination of clothing and bed linen. Profuse salivation increases caregiver burden as well. Psychologically, profuse salivation leads to lower self-esteem and social isolation. Pulmonary aspiration is the most serious complication of sialorrhea. Injections of botulinum toxins in the large salivary glands and the m. cricopharyngeus are the most effective method of treatment.

Keywords:

salivaton

sialorrhea

hypersalivation

ptyalism

dysphagia

stroke

botulinum toxin

salivary glands

Authors:

Zalialova Z.A.

Kafedra nevrologii i reabilitatsii Kazanskogo gosudarstvennogo meditsinskogo universiteta

Close metadata

References:

https://ru.wikipedia.org/wiki/%D0%A1%D0%BB%D1%8E%D0%BD%D0%B0.
Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins. Toxins. 2013;5:1010-1031. doi:10.3390/toxins5051010
Fiziologija cheloveka. Pod. red. Pokrovskogo VM, Korot'ko GF. M.: Medicina; 2007. (In Russ.).
Bavikatte G, Squires N, Wills A, Rowson J. The management of drooling in adults with neurological conditions. Current Opinion in Otolaryngology & Head and Neck Surgery. 2012;20(3);171-176. doi:10.1097/moo.0b013e32835328ec
Boyce W, Wood RK. Esophageal Dysmotility, Gastro-esophageal Reflux Disease, and Lung Transplantation: What Is the Evidence? Current Gastroenterology Reports. 2015;17(12). doi:10.1007/s11894-015-0474-9
Merello M. Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management. Drugs Aging. 2008;25:1007-1019. doi:10.2165/0002512-200825120-00003
Daniels SK, Ballo LA, Mahoney MC, Foundas AL. Clinical predictors of dysphagia and aspiration risk: outcome measures in acute stroke patients. Arch Phys Med Rehabil. 2000;81:1030-1033. doi:10.1053/apmr.2000.6301
http://health-ua.com/article/2863.html
Shnajder NA, Bahtina EA. Postinsul'tnaja disfagija. Vestnik Klinicheskoj bol'nicy. 2008;51(3):12-16. (In Russ.).
Nobrega AC, Rodrigues B, Melo A. Is silent aspiration a risk factor for respiratory infection in Parkinson’s disease patients? Parkinsonism Relat Disord. 2008;14:646-648. doi:10.1016/j.parkreldis.2007.12.007
Zaljalova ZA. Hypersalivation in Parkinson’s disease: causes and treatment options Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;10:58-64.
10.17116/jnevro201511510271-77
Ruvinskaya GR, Zalyalova ZА, Munasipova SE, Kuznetsova RG. Characteristics of ultimate oral fluid composition of patients with Parkinson’s disease Prakticheskaja medicina. 2013;1(69):91-95. (In Russ.).
Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G, Nascimbene C, Pignataro L. Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otolaryngol. 2008;29(5):333-338. doi:10.1016/j.amjoto.2007.10.003
Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002;112(1):73-81. doi:10.1097/00005537-200201000-00014
Tan EK, Lo Y, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190(1-2):95-97. doi:10.1016/s0022-510x(01)00565-2
Leder SB, Suiter DM, Green BG. Silent aspiration risk is volumedependent. Dysphagia 2011;26:304-309. doi:10.1007/s00455-011-9349-x
Park H-D, Kim H-J, Park S-J, Choi Y-M. Comparing the effect of botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion. Ann Rehabil Med. 2012;36(6):841-848. doi:10.5535/arm.2012.36.6.841
Mann G, Hankey GJ, Cameron D. Swallowing function after stroke. Prognosis and prognostic factors at 6 months. Stroke. 1999;30:744-748. doi:10.1161/01.str.30.4.744
Heine RG, Catto-Smith AG, Reddihough DS. Effect of antireflux medication on salivary drooling in children with cerebral palsy. Dev Med Child Neurol. 1996;38(11):1030-1036.
Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of anew treatment botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997;48(4):337-339. doi:10.1016/s0306-9877(97)90103-1
Lim M, Mace A, Nouraei SA, Sandhu G. Botulinum toxin in the management of sialorrhoea: a systematic review. Clin Otolaryngol. 2006;3(4):267-272. doi:10.1111/j.1749-4486.2006.01263.x
Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord. 2011;27(2):219-226. doi:10.1002/mds.23929
Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, Siciliani L, Sabatelli M, Bentivoglio AR. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011;26(2):313-319. doi:10.1002/mds.23473
Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001;70(4):538-540. doi:10.1136/jnnp.70.4.538
Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, Truong D. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;1(67):141-152. doi:10.1016/j.toxicon.2012.10.020
Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281. doi:10.1212/wnl.61.9.1279
Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18(6):685-688. doi:10.1002/mds.10420
Turk-Gonzales M, Odderson IR, Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands. Neurorehabil Neural Repair. 2005;19(1):58-61. doi:10.1177/1545968304273201
Park H-W, Lee W-Y, Park G-Y, Kwon DR, Lee ZI, Cho YW, Ahn SH, Lee DK. Salivagram After Gland Injection of Botulinum Neurotoxin A in Patients With Cerebral Infarction and Cerebral Palsy. Physical Medicine and Rehabilitation. 2012;4:312-316. doi:10.1016/j.pmrj.2011.12.008
Petracca M, Guidubaldi A, Ricciardi L, Ialongo T, Del Grande A, Mulas D, Di Stasio E, Bentivoglio AR. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview. Toxicon. 2015;1:107(A):129-140. doi:10.1016/j.toxicon.2015.08.014
Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry. 2001;70(3):417-418. doi:10.1136/jnnp.70.3.417
Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope. 2002;112(1):73-81. doi:10.1097/00005537-200201000-00014
Jeung IS, Lee S, Kim HS, Yeo CK. Effect of botulinum toxin A injection into the salivary glands for sialorrhea in children with neurologic disorders. Ann Rehabil Med. 2012;36(3):340-346. doi:10.5535/arm.2012.36.3.340
Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry. 1999;67(5):697. doi:10.1136/jnnp.67.5.697
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21(5):704-707. doi:10.1002/mds.20793
Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol. 2008;50(2):123-128. doi:10.1111/j.0012-1622.2008.02010.x
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Longlasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009;256(4):563-567. doi:10.1007/s00415-009-0085-1
Erasmus CE, Van Hulst K, Van Den Hoogen FJ, Van Limbeek J, Roeleveld N, Veerman EC, Rotteveel JJ, Jongerius PH. Thickened saliva after effective management of drooling with botulinum toxin A. Dev Med Child Neurol. 2010;52(6):114-118. doi:10.1111/j.1469-8749.2009.03601.x
Khan WU, Campisi P, Nadarajah S, Shakur YA, Khan N, Semenuk D, McCann C, Roske L, McConney-Ellis S, Joseph M, Parra D, Amaral J, John P, Temple M, Connolly B. Botulinum toxin a for treatment of sialorrhea in children. An effective, minimally invasive approach. Arch Otolaryngoi Head Neck Surg. 2011;137(4):339-344. doi:10.1001/archoto.2010.240
Tiigimae-Saar J, Leibur E, Kolk A, Talvik I, Tamme T. Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study. Int J Oral Maxillofac Surg. 2012;41(12):1540-1545. doi:10.1016/j.ijom.2012.09.015
Chan KH, Liang C, Wilson P, Higgins D, Allen GC. Long-term safety and efficacy data on botulinum toxin type A: an injection for sialorrhea. JAMA Otolaryngol Head Neck Surg. 2013;139(2):134-138. doi:10.1001/jamaoto.2013.1328
Basciani M, Di Rienzo F, Fontana A, Copetti M, Pellegrini F, Intiso D. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Developmental Medicine & Child Neurology. 2011;53(6):559-564. doi:10.1111/j.1469-8749.2011.03952
Sriskandan N, Moody A, Howlett DC. Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy. Br J Oral Maxillofac Surg. 2010;48(1):58-60. doi:10.1016/j.bjoms.2009.03.005
Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg. 2003;61:454-457. doi:10.1053/joms.2003.50086
Ko SH, Shin YB, Min JH, Shin MJ, Chang JH, Shin YI, Ko HY. Botulinum toxin in the treatment of drooling in tetraplegic patients with brain injury. Ann Rehabil Med. 2013;37(6):796-803. doi:10.5535/arm.2013.37.6.796
Terré R, Panadés A, Mearin F. Botulinum toxin treatment for oropharyngeal dysphagia in patients with stroke. Neurogastroenterology & Motility. 2013;25:11:896-702. doi:10.1111/nmo.12213
Mazlan M, Rajasegaran S, Engkasan JP, Nawawi O, Goh KJ, Freddy SJ. A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases Toxins. 2015;7:3758-3770. doi:10.3390/toxins7093758